A reanalysis of Sweden’s population-based fecal occult blood test (FOBT) screening program suggests that the mortality benefit of colorectal cancer screening may have been substantially underestimated. Researchers analyzed 376,511 adults aged 60–69 years in the Stockholm-Gotland region, using a prospective cohort design in which birth cohorts were assigned to receive screening invitations at different times. The original analysis had estimated a 14% reduction in CRC mortality associated with being invited to screening, but the researchers identified two sources of bias: contamination of the control group, in which about two-thirds of controls were eventually invited to screening, and CRC deaths occurring…
Author: Abhay Panchal
BioNTech is ending a mid-stage trial of its experimental personalized mRNA cancer vaccine, autogene cevumeran, after an independent committee concluded it was unlikely to improve survival in patients with high-risk, mid-stage colorectal cancer. The Phase 2 study enrolled patients who had undergone surgery and chemotherapy but still had detectable circulating tumor DNA (ctDNA), testing whether the vaccine could prevent recurrence. The committee also identified a numerical imbalance in overall survival between the vaccine and control groups; Reuters reports this likely reflected more deaths in the vaccine arm, although the magnitude was unclear.
Researchers at Nanyang Technological University developed peptide microdroplets that deliver siRNA into T cells and colorectal cancer cells to suppress PD-1 and PD-L1 production. In mouse models of microsatellite-stable (MSS) colorectal cancer, which accounts for about 85% of CRCs and generally responds poorly to checkpoint inhibitors, the dual-siRNA approach reduced tumor growth by about 67%, comparable to the antibody combination used as a benchmark. The approach could potentially offer a lower-cost alternative to monoclonal antibody immunotherapy; researchers estimate manufacturing costs could be 5–10 times lower if the technology translates successfully to treatment. However, this remains an early preclinical finding: the…
As colonoscopy reimbursement declines and GI practices see more patients with functional disorders, obesity, MASLD, and nutrition-related concerns, two gastroenterologists describe how they have expanded beyond procedure-based care into metabolic, lifestyle, and gut-health services. Their models differ: one uses shared medical appointments within an insurance-based practice, while the other combines reimbursed nutrition services with a direct-pay integrative medicine arm. The article highlights the practical requirements behind these programs: team-based staffing, dietitians, structured group visits, appropriate payer models, and physician expertise. The physicians argue that current fee-for-service reimbursement still favors procedures, making nonendoscopic care difficult to sustain on physician time alone,…
New studies suggest that physical activity may decline rather than increase after starting GLP-1 medications, despite recommendations to exercise to help preserve lean mass. In a retrospective study of 753 GLP-1 users with wearable-tracker data, average daily steps fell from 5,047 to 4,487, while moderate-to-vigorous activity dropped from 27.9 to 22.2 minutes per day. A separate study found that 57.7% of GLP-1 users failed to meet the recommended 150 minutes of moderate-to-vigorous activity per week, with average sedentary time approaching 16 hours/day.
Experts at the 2026 ESPGHAN Congress emphasized that AI in pediatric gastroenterology should remain a decision-support tool, not a substitute for physician judgment. The most promising applications include AI-assisted endoscopy, histology, imaging, and monitoring for IBD relapse, as well as nutrition-related tasks such as malnutrition screening and parenteral nutrition planning. A key caveat is that adult AI models cannot simply be transferred to children. Pediatric-specific validation, prospective trials, harmonized datasets, and ongoing monitoring for model performance and drift are needed before wider clinical adoption. In steatotic liver disease, the discussion also highlighted that simpler models using routine clinical and laboratory…
Ayble Health has joined Amazon’s Health Benefits Connector, giving eligible customers a direct way to discover, verify coverage for, and enroll in virtual GI care. Ayble, the first digestive health provider on the platform, says it is in-network for more than 80 million Americans and offers multidisciplinary care—including nutrition counseling, medication management, diagnostic testing, and behavioral health support—with care teams typically assigned within 48 hours. The move comes amid significant gaps in GI access: the company cites estimates that nearly 70% of U.S. counties have no practicing gastroenterologist and a projected national shortage of 1,630 full-time GI physicians. For Scope…
Carelon Health Services will add Guardant Health’s Shield blood test to its colorectal cancer screening coverage guidelines effective Nov. 15, 2026, expanding commercial coverage to approximately 90 million people ages 45 and older, according to Guardant. The company says this represents about 75% of the U.S. population eligible for average-risk CRC screening and marks another major expansion of coverage for the FDA-approved blood-based screening test. Shield is intended for average-risk adults 45 and older and can be completed through a routine blood draw; patients with a positive result should be referred for colonoscopy. Guardant reports that more than 200,000 Shield…
Starting Oct. 1, 2026, UnitedHealthcare will eliminate advance-notification requirements for select GI endoscopy procedures—including EGD, capsule endoscopy, and diagnostic and surveillance colonoscopy—for commercial and Oxford plan members. The insurer will also end site-of-service medical-necessity reviews for GI procedures performed in hospital outpatient settings, including screening colonoscopy. The move reverses the notification process UHC introduced after withdrawing its controversial 2023 prior-authorization proposal and comes as part of a broader effort to reduce utilization-management requirements. UHC has separately announced that roughly 1,700 codes will come off prior authorization across its plans, following its commitment to reduce remaining prior-authorization volume by 30% by…
A routine endoscope demonstration at a Texas hospital allegedly turned into a medical-device mishap when a pressurized water bottle connected to a CO₂ insufflator burst, causing severe hearing damage to a hospital employee wearing hearing aids. She is now seeking more than $1 million in damages, including medical costs, lost wages and pain and suffering. Fujifilm disputes responsibility, arguing that a hospital employee activated the CO₂ valve despite instructions to turn it off. The case raises an unusual but important question around safety protocols for equipment demonstrations and handling pressurized endoscopy systems.